NextFin News - The S&P 500 Health Care Index climbed 10% through Tuesday, outperforming every one of the benchmark's other 10 sectors while the broader index fell 1.1%, as investors pulled money out of artificial-intelligence darlings and into drugmakers that still earn profits today. The rotation is not subtle: Eli Lilly has surged 29% since the end of October to become the first health-care company valued at $1 trillion, and Regeneron, Merck and Biogen have each gained at least 18% in the same stretch. After nearly two years in which AI was the only trade that mattered, the market is asking a question it has not asked since 2021: what if the machines were priced for perfection and the medicine was priced for neglect?
The Rotation in Numbers
The move is broad, deep, and - for once - not being led by a single weight-loss-drug story. Across the month, the S&P 500 Health Care Index gained roughly 8% while the S&P 500 Information Technology Index fell 3-4%, according to market data compiled by Saxo's investment-strategy team. Eli Lilly, Cardinal Health, Regeneron, Biogen and Merck were among the strongest contributors, with several delivering 20-30% monthly gains.
The flow data confirms the price action. Global healthcare exchange-traded funds attracted $6.8 billion in November 2025, the largest monthly inflow in five years, according to iShares/BlackRock. The iShares Global Healthcare ETF, which tracks the S&P 1200 Global Healthcare Index, returned 12% in the three months to November - double its 6% long-run average annual return since inception. This is not retail chasing a meme; it is institutional money repricing an entire sector.
Why now? Three forces collided. First, AI stocks ran into a wall of skepticism about whether the revenue can justify the capital expenditure. Second, macro uncertainty rose, pushing investors toward sectors with earnings that do not depend on the next chip cycle. Third, healthcare itself stopped looking broken: drug-pricing politics eased after the White House secured most-favored-nation pricing agreements with 14 of the 17 largest pharmaceutical companies in December 2025, and the FDA approved 50 new drugs in 2024, above the 10-year average.
The valuation gap that made this possible had been widening for years. Using FactSet data as of early December 2025, the S&P 500's forward 12-month price-to-earnings ratio stood at 22.8x, above its 10-year average of 18.6x, while the health-care sector's forward multiple sat near 15.6x - equal to its own 10-year average. That leaves healthcare trading at roughly a 30% discount to the broader market, one of the widest gaps in decades. At the peak of the AI frenzy in 2025, when NVIDIA briefly became the first company to top $4 trillion in market value, the entire US healthcare sector's capitalization looked small beside a single chip designer. A sector that heals people was priced as if it had less future than a single supplier of the machines building the machines.
The Mechanism: Why the Trade Works - and Why It Is Not Just Fear
The lazy explanation is that investors got scared of AI and ran to safety. That is part of it, but it misses the mechanism. The rotation works because healthcare offers something the AI complex cannot: earnings visibility measured in quarters, not in promises measured in years.
Consensus expects S&P 500 healthcare earnings to grow 12-15% in 2025, ahead of the 10-12% expected for the broader index. That growth is not speculative. It is anchored in GLP-1 obesity and diabetes drugs, where global spending is projected to exceed $100 billion by 2030. Eli Lilly's combined Zepbound and Mounjaro sales reached nearly $19 billion in the first nine months of 2025, leapfrogging Merck's Keytruda to become the world's best-selling drug. These are revenues booked today, not discounted dreams of 2030.
The transmission channel runs through the discount rate and the credibility of the cash flow. When investors doubt whether an AI company's capital spending will ever earn its cost of capital, they raise the discount rate applied to its distant earnings - which crushes valuation even if the long-term story is intact. Healthcare cash flows, by contrast, sit inside patent-protected monopolies with inelastic demand. A patient does not stop taking a cancer drug because the yield curve steepened. That durability is what gets re-rated when risk appetite narrows.
Hedge funds have been the clearest signal. Goldman Sachs' prime-brokerage data shows funds aggressively bought health-care stocks in the second half of 2025, driven almost entirely by long purchases and concentrated in biotech. Specialised healthcare hedge funds returned roughly 40% between August 2025 and April 2026, compared with 17% for generalist equity long-short funds. New fund launches tell the same story: 24% of this year's new hedge funds are dedicated to healthcare, the highest share since at least 2009. When the smart money that sat out healthcare for a decade starts launching dedicated vehicles, the rotation has legs.
"Markets have been dominated by AI-driven leadership for much of the past two years, but the recent combination of AI-bubble concerns and rising macro uncertainty - including signs of softer US economic data - is encouraging investors to take a more defensive stance," said Charu Chanana, chief investment strategist at Saxo. "This shift does not signal the end of the AI theme. Rather, it highlights a more discerning market environment that demands clearer monetisation pathways and manageable balance-sheet commitments before rewarding AI-linked businesses with further gains."
That last sentence is the key. The market is not abandoning AI. It is becoming selective - and that selectivity is what is lifting healthcare, because healthcare's monetisation pathway is already visible in the P&L.
Cyclical or Structural? The Call
This is the question that determines whether the trade is a month-long bounce or a multi-year rerating. The answer is both - and confusing them is how investors lose money.
The cyclical leg is the rotation itself. Money moved because AI valuations stretched, because macro data softened, and because positioning in technology was crowded. Those are mean-reverting forces. When AI earnings catch up to the hype - or when macro data stabilises - some of this money will flow back. History supports this: healthcare led the market in the defensive rotations of 2000-2002 and 2008, then lagged badly when risk appetite returned. A rotation born of fear reverts when fear fades.
But the structural leg is real and separate. Healthcare's earnings engine has genuinely changed. GLP-1 drugs have created a durable, expanding market that did not exist five years ago. FDA approval productivity has improved, with 50 approvals in 2024 above the decade average. Oncology, neurology and metabolic disease now have credible blockbuster pipelines. And the sector's valuation discount to the market is near a multi-decade wide - a structural mispricing, not just a cyclical dip. Even if the rotation reverses, the starting valuation was so depressed that the medium-term path of least resistance remains upward.
So the call: the flow-driven surge is cyclical and will partially reverse; the valuation rerating is structural and will not fully unwind. Investors who treat this as purely a fear trade will exit too early. Investors who treat it as the end of AI will get run over when the technology leaders report earnings that justify their multiples.
The Second-Order Consequence Nobody Is Pricing
Everyone sees the first-order effect: money out of AI, into drugs. The second-order effect is what happens to capital formation in both sectors - and it cuts against the consensus.
If healthcare stays re-rated, biotech funding improves, M&A accelerates, and small innovators get bought at prices that reward venture capital. That is the bullish case for the sector's innovation pipeline. But the same re-rating raises the opportunity cost of capital for AI infrastructure. A pharmaceutical company that can compound at mid-teens on protected cash flows becomes a credible alternative to a chip company burning billions on data centres. The marginal dollar of institutional capital now has a choice it did not have in 2023 - and that choice is a headwind for AI's capital-intensive second act.
Conversely, the rotation creates a trap inside healthcare itself. The winners are the companies with visible earnings - Lilly, Novo Nordisk, AbbVie - not the speculative biotechs with no revenue. AbbVie illustrates the pattern: third-quarter 2025 net revenues from its immunology portfolio rose 11.9% to $7.885 billion, with Skyrizi at $4.708 billion, up 46.8%, and Rinvoq at $2.184 billion, up 35.3%. The company raised its full-year adjusted earnings guidance for a third straight quarter. Yet the stock still trades at roughly 19 times forward earnings, below its own history. The market is rewarding cash flow, not stories. Any biotech without a path to profitability will not participate, no matter how elegant its science.
The third-order gap is the expectation embedded in Lilly itself. At $1 trillion, Lilly is now two-thirds as valuable as Meta, worth more than Walmart, and more than double Johnson & Johnson. Shares were under $100 as recently as 2018 and now trade above $1,048. The obesity market is expected to reach $100 billion annually by 2030, and Lilly is the share leader - but at a $1 trillion valuation, much of that growth is already priced. The rotation lifted Lilly on its coattails, but Lilly is no longer a defensive value play. It is a momentum stock wearing a pharma uniform.
The Strongest Case Against the Trade
The bear case is not that healthcare is a bad sector. It is that the rotation is a positioning unwind, not a fundamental awakening - and positioning unwinds reverse fast.
Drug-pricing risk has not disappeared; it has merely paused. The most-favored-nation agreements signed by the largest drugmakers could be renegotiated, and US election cycles historically bring pricing pressure back. Patent cliffs loom: Merck's Keytruda, the world's best-selling drug, loses exclusivity in 2028, and several large pharma names face expiries in the coming years. Clinical-trial risk remains binary - a single failed Phase III study can erase years of gains. And GLP-1 competition is intensifying, with next-generation obesity drugs from Lilly itself and rivals threatening to cannibalise today's blockbusters.
More fundamentally, the AI thesis has not been disproven. If the megacap technology companies report that AI capital expenditure is generating the revenue growth investors were promised, the discount-rate argument for healthcare collapses. AI earnings are still growing faster than healthcare earnings; the gap is valuation, not fundamentals. A rotation based on valuation compression alone is vulnerable to an earnings surprise.
The falsifying signal is specific: if the S&P 500 Information Technology Index recovers its losses and reclaims outperformance versus healthcare for three consecutive months while AI megacaps report revenue growth above 20% year over year, the structural-rerating thesis is wrong and this was purely a cyclical fear trade. Watch the ratio of the healthcare ETF to the technology ETF - a sustained break lower from current levels ends the story.
What to Watch: Scenarios by Time Horizon
Short term (1-3 months): Sentiment and flows dominate. The base case is continued outperformance as the $6.8 billion November inflow is followed by more positioning normalization. The upside case is an acceleration if AI stocks weaken further on earnings disappointment. The downside case is a sharp reversal if macro data stabilises and risk appetite returns - the same flows that rushed in can rush out.
Medium term (6-18 months): Fundamentals take over. The base case is healthcare earnings growing 12-15%, supporting a gradual narrowing of the valuation discount from 30% toward its historical norm. The upside case is a wave of M&A as large pharma deploys cash to refill pipelines ahead of patent cliffs. The downside case is a return of drug-pricing headlines or a cluster of failed trials.
Long term (3-5 years): The structural leg decides. The base case is that GLP-1 markets reach $100 billion annually, FDA productivity stays above average, and healthcare compounds at mid-teens - a genuine second growth engine for portfolios that were over-concentrated in chips. The upside case is that AI-driven drug discovery - Regeneron's genetics platform, Merck's generative-AI partnerships - materially shortens development timelines and lifts industry-wide R&D productivity. The downside case is that pricing regulation returns with force and the obesity market saturates faster than expected.
For investors, the implication is asymmetry, not certainty. Healthcare offers a second growth engine driven by demographics rather than chip cycles - but it carries its own risks: reimbursement pressure, regulatory scrutiny, and trial-driven volatility. The companies best positioned are those with visible cash flow today - Lilly, Novo Nordisk, AbbVie, Merck - and the innovators with credible paths to approval, not the speculative names riding sector beta.
The market spent two years asking only one question: how much AI is enough? It is now asking a second: how much medicine is too cheap? The answer to the first was a bubble. The answer to the second is still being written - and for the first time since the pandemic, it is being written by investors who are willing to pay for earnings they can hold, not just narratives they can imagine.
Explore more exclusive insights at nextfin.ai.
